Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13557
UPID:
KCC2D_HUMAN
Alternative names:
-
Alternative UPACC:
Q13557; A8MVS8; Q52PK4; Q59G21; Q8N553; Q9UGH6; Q9UQE9
Background:
Calcium/calmodulin-dependent protein kinase type II subunit delta plays a pivotal role in Ca(2+) homeostasis and excitation-contraction coupling in the heart. It targets ion channels, transporters, and proteins involved in Ca(2+) dynamics, contributing to heart function and response to myocardial infarction. Its activity affects transcription factors and signaling molecules, influencing cardiac hypertrophy and heart failure.
Therapeutic significance:
Understanding the role of Calcium/calmodulin-dependent protein kinase type II subunit delta could open doors to potential therapeutic strategies for heart diseases, including dilated cardiomyopathy and heart failure.